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Abstract
Liver cancers in children are rare representing only 1.1% of malignancies, with an annual incidence rate of 1.5 cases
per million. Hepatoblastoma and hepatocellular carcinomas are the most common malignancies of the liver oc-
curring in young people aged 15 years or younger. Molecular basis of both tumors are still unclear, and common
markers (i.e., CTNNB1, APC, IGF-2) are not always useful in the characterization of sporadic forms; in this respect,
microRNA recently associated with carcinogenesis could play a pivotal role in their onset. CTNNB1 and APC were
analyzed by sequencing, and IGF-2 promoter methylation status was assessed by methylation-specific polymerase
chain reaction. MicroRNA expression was assayed by microarray and quantitative reverse transcription–polymerase
chain reaction in hepatoblastoma samples. Although few genomic alterations were detected in ours samples, an al-
tered expression of somemicroRNA in hepatoblastomawas observed. Unsupervised clustering shows thatmicroRNA
profile can distinguish tumor from nontumor tissues. Further analyses of microRNA contents in hepatoblastoma
compared with hepatocellular carcinoma highlighted four upregulated microRNA (miR-214, miR-199a, miR-150 [P <
.01], and miR-125a [P < .05]) and one downregulated microRNA (miR-148a [P < .01]). In conclusion, although our
samples were poorly informative from a genetic point of view, they showed a peculiar microRNA expression pattern
compared with nontumor tissues and hepatocellular carcinoma.MicroRNA could represent valid markers for the clas-
sification of pediatric liver tumors.
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Introduction
Hepatoblastoma (HB) and hepatocellular carcinoma (HCC) are two
different subtypes of primary tumors arising from liver parenchymal
cells [1]. Hepatoblastoma is a rare liver cancer with an incidence in
western countries of 1.5 cases per million of individuals younger than
15 years. Despite this, it is the most common hepatic malignancy
during childhood [1–3]. By contrast, HCC is a common solid cancer
in adults: it is a complex and heterogeneous malignancy with several
genomic alterations. Aberrant activation of several signaling cascades,
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such as, phosphoinositol 3-kinase/mammalian target of rapamycin,
Wnt, Hedgehog, insulin-like growth factor 2 (IGF-2), and apoptotic
signaling have been extensively described in both HB and HCC [1,2].
Most cases of HB are sporadic, but children with familial adeno-
matous polyposis and Beckwith-Wiedemann syndrome have a higher
risk for HB [1]. Although specific chromosome aberrations have not
been linked with prognosis or casual factors, genetic disorders have
been described in chromosomes 1q, 2q, 7q, 8, 17q, and 20 [4–6].
Activation of wingless (Wnt) signaling pathway through mutations
in β-catenin (CTNNB1) may contribute to the development of HCC
and HB [7–10]. β-Catenin is the central mediator of the well-known
Wnt/β-catenin signaling pathway, which acts as a gene transcription
(co)factor activating the T-cell factor/lymphoid enhancer factor [7,8].
In HB, mutations leading to constitutive activation of β -catenin
have been identified in genes of the Wnt/β-catenin pathway: they
occur with high frequency (48%-89%) in exon 3 of CTNNB1 and
are mainly characterized by deletions or point mutations [10]. More-
over, an increased level of gene expression of IGF-2 compared with
normal livers has been reported in a high proportion of human HB.
In the fetal liver, promoters P2, P3, and P4 are active and expressed
monoallelically; P3 is the most active promoter and P1 is inactive.
However, in the adult liver, P1 becomes dominant and is biallelically
expressed, and P2, P3 and P4 activities are decreased or lost [11]. In
addition, P4 hypomethylation has been shown in several human can-
cers, including HCC, suggesting that it may be an early end common
event in hepatocarcinogenesis [12]. Although the exact mechanism
leading to these alterations is not entirely certain, it seems that loss
of imprinting (LOI) and/or promoter demethylation are at least partly
involved [13].
MicroRNA (miRs), an abundant class of noncoding small RNA
∼21 nt, have been shown to play important roles in various cellular
and pathogenic processes, including cellular development, immu-
nologic response, and carcinogenesis [14–17]. Typically, they can
modulate gene expression by regulating the messenger RNA at a post-
transcriptional stage, aligning with sequences in the 3′-untranslated
region [14,18–20]. MicroRNA can target oncogenes or tumor sup-
pressor genes, contributing to the initiation and progression of many
human cancers [21–23]. Several microRNA have been linked to ini-
tiation and progression of human cancers: miR-15a and miR-16 in
chronic lymphocytic leukemia [24]; miR-145 in colon carcinoma,
lung, breast, and prostate [25–29]; and miR-21 in glioblastoma
[30]. Many well-known proteins involved in carcinogenesis are reg-
ulated by microRNA; for example, phosphatase and tensin homolog
(PTEN) tumor suppressor is regulated by miR-21 and miR-214
[31,32], tumor suppressor protein p27kip1 is regulated by miR-221
and miR-222 [33], E2F1 transcription factor is regulated by the
miR-17-92 cluster [34], and BCL-2 antiapoptotic gene is regulated
by miR-15a/miR-16 cluster [22].
Despite recent studies show that many microRNA are dysregulated
in HCC [29,35–40] such as miR-145, miR-199a, miR-21, miR-34a,
miR-221/222, and miR-224, no data are available on microRNA ex-
pression in HB patients yet.
In this study, we analyzed samples from nine HB patients, namely,
three snap-frozen and six paraffin-embedded (FFPE) tissues. Gene
expression profiling for microRNA on three snap-frozen matched
samples was carried out to evaluate the global content of microRNA;
results were validated by quantitative reverse transcription–polymerase
chain reaction (qRT-PCR) in the same samples and in six additional
matched (FFPE) tissues.
Materials and Methods
Tissue Samples and Clinical Data
The tissue samples analyzed in this study were obtained from pa-
tients undergoing a surgical procedure to remove a portion of the
liver at the “Bambino Gesù” Hospital (Rome, Italy). Written in-
formed consent for biologic studies was obtained from all patients
analyzed, in accordance with the Declaration of Helsinki. Pathologic
analysis by the institute providing the surgical specimens confirmed
the histopathologic diagnosis of the samples taken for research.
We included in our study nine HB tumor samples (HBT) and their
surrounding tissues not showing neoplastic features (from now called
“normal tissue NT”). Their sex distribution was as follows: six males
and three females (Table 1). All patients underwent SIOPEL chemo-
therapy treatment protocols. Six matched samples were FFPE (HBT1/
NT1, HBT3/NT3, HBT5/NT5, HBT7/NT7, HBT9/NT9, and
HBT11/NT11), whereas the three remaining samples were fresh-
frozen (HBT13/NT13, HBT15/NT15, and HBT17/NT17). Tissues
were collected from children aged between 8 and 39 months.
Nucleic Acid Extraction
DNA was extracted from samples using a standard proteinase K di-
gestion and phenol/chloroform extraction; DNA was stored at +4°C in
Tris-EDTA solution.
RNAwas extracted using a standard Trizol RNA (Invitrogen, Milan,
Italy) extraction method according to the manufacturer’s instructions.
The quality of nucleic acids was assessed by agarose gel electrophoresis,
and concentrations were determined through Nanodrop ND-1000
(Thermo Scientific, Waltham, CA).
Mutational Analyses of DNA
DNA from samples was amplified by PCR with specific primers
tailored for exon 3 of CTNNB1 gene (BCAT-1/BCAT-2: 5′-GATTT-
GATGGAGTTGGACATGG-3′; 5′-TGTTCTTGAGTGAAG-
GACTGAG-3′) and exon 15 of APC gene (Fw: 5′-ACCTCCAAC-
CAACAATCAGC-3′; Rev: 5′-CTTTGGATGACTGGGGAAAA-3′).
After PCR amplification, products were purified using spin columns
(QIAquick PCR purification kit; Qiagen, Inc., Milan Italy) and se-
quenced (CEQ 2000 XL DNA Analysis System; Beckman Coulter,
Fullerton, CA).
Table 1. Clinical and Pathologic Characteristics of Patients with HB.
Case No. Age (months)/Sex Histologic Subtype* CTNNB1† APC ‡ IGF-2§
P2A P2B P3 P4
HBT1 8/♀ Epithelial (F/E) WT WT ND ND ND ND
HBT3 39/♂ Epithelial (E) WT WT ND ND ND ND
HBT5 17/♂ Epithelial (F/E) WT WT ND ND ND ND
HBT7 34/♀ Epithelial (E) WT WT ND ND ND ND
HBT9 24/♀ Mixed A43D WT ND ND ND ND
HBT11 23/♂ Epithelial (F/E) WT WT ND ND ND ND
HBT13 11/♂ Epithelial (F) T40S WT +/+ +/+ +/+ −/−
HBT15 6/♂ Epithelial (F/E) WT WT +/+ +/+ +/+ −/−
HBT17 26/♂ Epithelial (F) WT WT +/+ +/+ +/+ −/−
Tumor tissues examined in this study were collected at time of surgery or biopsy of primary treated
tumors after chemotherapy.
*Predominant epithelial component is given in parentheses: E indicates embryonal differentiation
only; F, fetal differentiation only; F/E indicates fetal and embryonal differentiation detectable.
†β-Catenin exon 3 characterization by sequencing: WT indicates wild type.
‡APC exon 15 characterization by sequencing: WT indicates wild type.
§IGF-2 promoter methylation assay by MSP: ND indicates not determined; +, methylated;
−, unmethylated.
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For the detection of deletions, genomic DNA from HBT and NT
tissues was amplified using the primer pairs BCAT-3/BCAT-4,
BCAT-1/BCAT-6, flanking exons 2, 3, and 4 of the CTNNB1 gene:
BCAT-3, 5′-AAAATCCAGCGTGGACAATGG-3′; BCAT-4, 5′-
TGTGGCAAGTTCTGCATCATC-3′; BCAT-6, 5′-GGAGGA-
AGGTCTGAGGAGCAG-3′ [41].
Methylation-Specific PCR (MSP)
Methylation-specific PCR (MSP) was used to assess CpG site meth-
ylation within promoters (P) 2, 3, and 4 of the IGF-2 gene: in partic-
ular, two MSP assays (P2A and P2B) were developed to evaluate
methylation in P2. A lack of CpG sites within P1 limited its evalua-
tion by MSP. Methylation-specific PCR was performed using the
CpGenome DNA modification kit (Chemicon International, Milan,
Italy). Briefly, 1 μg of genomic DNA was processed according to the
manufacturer’s instructions. Relative locations of the MSP assays and
primers used in the assays are shown elsewhere [42].
μParaflo MicroRNA Microarray Assay
Microarray assay was performed on a custom array by a service
provider (LC Sciences, Houston, TX). A 5-μg total RNA sample
was extracted as previously described. Data were analyzed by first
subtracting the background and then normalizing with a cyclic
LOWESS filter (locally weighted regression). Interarray quantile nor-
malization was performed using function “quantile.normalize” from
R (www.r-project.org) package “affy” using default settings [43].
Finally, data were filtered to remove probes with constitutively low
expression. Across patients, we required interquartile range for
log2-transformed expression values across patients to be at least
equal to 0.5 or higher and for expression to be equal to log2(1000)
or higher in at least two samples. Altogether, this procedure reduced
the microRNA data set from 721 to 51 microRNA.
Cluster analysis was performed using the metric Euclidean dis-
tance to compute the distance matrix for HB patients based on the
expression of 51 differentially expressed microRNA. To agglomerate
the patients in the hierarchical cluster, we used the Ward method.
Function heatmap.2 from R package gplots was used for the graphical
display of the dendrogram.
TaqMan Real-time RT-PCR
MicroRNA from FFPE tissues were extracted using mirVanamiRNA
Isolation kit (Ambion, Austin, TX). To evaluate mature microRNA in
a specific manner, TaqMan MicroRNA assay kits were purchased from
ABI (Foster City, CA) to detect miR-145 (catalog no. 4373133), miR-
214 (catalog no. 4373085), miR-451 (catalog no. 4373209), miR-195
(catalog no. 4373105),miR-125a (catalog no. 4373149),miR-150 (cat-
alog no. 4373127), miR-199a (catalog no. 4373272), miR-148a (cat-
alog no. 4373130), and control RNA (RNU6B, cat. catalog no.
4373381). It is a two-step protocol requiring reverse transcription
(catalog no. 4366536) with a microRNA-specific primer, followed
by real-time PCR with TaqMan probes (catalog no. 4324018). The
fold change of the microRNA gene in the tumor samples relative to
the nontumor ones was calculated using the 2−ΔΔCTmethod. For de-
tails, refer to the ABI user’s bulletin “Relative Quantitation of Gene
Figure 1. (A) Results of the unsupervised hierarchical clustering, in which NT tissues (blue) form a separate cluster from the HB tumors
(gray). The heat map shows relative levels of microRNA expression in a green (low relative expression) to red (high relative expression)
scale. (B) Volcano plot: a useful graphical that plots negative log10 P values (obtained from t test) on the y-axis versus mean log2 fold
change on the x-axis, comparing altered microRNA expression in HB patients showing significant alteration of a small number of specific
microRNA. Black dots indicate altered microRNA in HB versus NT tissues considered significant (P < .05).
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Expression: ABI PRISM 7700 Sequence Detection System: User Bul-
letin 2: Rev B.”
Pten transcripts were also evaluated using real-time PCR. One
microgram of total RNA from each sample was reverse-transcribed
using the TaqMan Reverse Transcription Reagents (Applied Biosys-
tems). For the PCR analysis, Gapdh was used as an internal control:
Gapdh primers (5′-GAA GGT GAA GGT CGG AGT C-3′ and 5′-
GAA GAT GGT GAT GGG ATT TC-3′) were designed using the
Primer Expression software (Applied Biosystems). The PCR primers
for Pten (5′-CGGCAGCATCAAATGTTTCAG-3′ and 5′-
AACTGGCAGGTAGAAGGCAACTC-3′) are described elsewhere
[31]. Real-time PCR was performed using the ABI PRISM 7000 Se-
quence Detection System (Applied Biosystems). In a total volume
of 20 μl of reaction mixture, 0.1 μg of complementary DNA tem-
plates were mixed with 10 μl of SYBR GREEN PCR Master Mix
(Applied Biosystems) and each pair of primers at a final concentra-
tion of 100 nM. The thermal cycling conditions were set up sequen-
tially as follows: denaturing at 95°C for 10 minutes and 40 cycles of
95°C for 15 seconds and 60°C for 1 minute. Each sample was as-
sayed in triplicates.
PTEN Western Blot
Frozen tissues were weighted and homogenized in an appropriate
amount of lysing Buffer A (Sigma-Aldrich, St. Louis, MO), supple-
mented with 0.6 U/ml of benzonase (Merck KGaA, Germany) and
protease inhibitor cocktails (Sigma-Aldrich) according to the manufac-
turers’ instructions. After protein quantification by Bradford protein
assay (Bio-Rad, Germany), 25 μg of whole protein extracts were
loaded onto a 10% SDS-PAGE and transferred to a polyvinylidene
fluoride membrane (Immobilon, Millipore, Billerica, MA). The blots
were probed with anti-PTEN monoclonal antibody (1:1000; Cell
Signaling, Beverly, MA) and with 1 μg/ml anti–β-actin monoclonal
antibody (Sigma-Aldrich) overnight at 4°C. After 1 hour of incuba-
tion with either an anti–rabbit or an anti–mouse secondary antibody
(1:2000; GE Healthcare, United Kingdom), the enhanced chemilumi-
nescence detection procedure was used to visualize antibody reaction
(ECL Kit; GE Healthcare).
Results
β-Catenin, APC, and IGF-2 Gene Characterization in
HB Tissues
Mutations in exon 3 of β -catenin and in APC gene are frequent in
HB. We performed mutational analysis to identify possible muta-
tions on both genes in our tissue samples.
Screening of HB samples showed a point mutation in HBT9 pa-
tient causing a A43D substitution and an additional point mutation
in HBT13 causing a T40S substitution; no other point mutation
and/or deletion were observed in β -catenin exon 3 and its flanking
regions. We also performed mutational analysis on APC gene, and no
mutations were detected in exon 15 in our HB samples (Table 1).
The Ig f2 gene transcription is driven by four promoters (P1-P4)
that produce distinct transcripts which vary by tissue type and de-
velopmental stage. To describe Ig f2 promoter activity, we analyzed
methylation status of selected CpG islands located in its promoters.
The analysis was conducted in the three frozen matched samples
(HBT13/NT13, HBT15/NT15, and HBT17/NT17). No differ-
ences were detected in P2, P3, and P4 promoters’methylation status
pattern in our samples; in particular, both P2 and P3 promoters were
found to be methylated in all HB samples. In contrast, P4 CpG is-
land, within promoter 4, was hypomethylated (Table 1).
MicroRNA Expression Profile in Human HBs
MicroRNA-related studies on cancers are currently based on the
different expression profile of microRNA in cancer versus normal tis-
sue. Differential expression of the candidate microRNA is a possible
approach to study the function of microRNA in cancer pathogenesis.
To assess the putative role of microRNA in HB, we performed mi-
croarray microRNA analysis.
Three matched frozen samples were measured by microarrays in
a cohort of nine matched samples of HB. Unsupervised clustering
(Figure 1A), performed by using processed data from microRNA mi-
croarray analysis, shows tumor samples and adjacent nonmalignant
tissues classified into two groups.
To identify the differentially expressed microRNA that cause clus-
tering of tumor versus nontumor tissues, we calculated mean log2
ratio of the signal between HBT/NT. Levels of significance and mag-
nitude of change in expression are represented in a volcano plot
(Figure 1B); 13 differentially expressed microRNA, showing a good
Table 2. MicroRNA Showing Different Pattern of Expression in HB Compared with the HCC.
MicroRNA Locus Expression
in HB Fold
Change*
Expression
in HCC
References
Upregulated
hsa-miR-10 17q2132 1.67 Up [38]
hsa-miR-10b 2q31.1 1.99 Up [45]
hsa-miR-125a-5p 19q133 0.93 Down [36]
hsa-miR-140-3p 16q22.1 1.25 ND
hsa-miR-143 5q33.1 1.06 Down [35]
hsa-miR-145 5q331 1.16 Down [38]
hsa-miR-150 19q133 1.71 Down [35]
hsa-miR-155 21q213 1.84 Up [46]
hsa-miR-15 13q143 0.67 Up [38]
hsa-miR-15b 3q26.1 1.12 ND
hsa-miR-181 1q313/
9q33
1.04 Down [35]
hsa-miR-195 17p131 0.93 Down [35,36,40]
hsa-miR-199a-3p 1q243 0.99 Down [36]
hsa-miR-199a-5p 1q243 1.60 Down [36]
hsa-miR-214 1q243 0.85 Down [35,39,46]
hsa-miR-221 Xp113 1.00 Up [35]
hsa-miR-342-3p 14q322 1.08 ND
hsa-miR-574-5p 4p14 0.83 ND
hsa-miR-923 17q12 0.70 ND
hsa-miR-98 Xp1122 1.09 Up [40]
hsa-Let-7* 19q1333 0.97 Up [40]
Downregulated
hsa-miR-106 Xq262 −0.98 Up [47]
hsa-miR-122* 18q2131 −2.46 ND
hsa-miR-148 7p152 −2.28 Up [41]
hsa-miR-149* 2q373 −0.74 ND
hsa-miR-17 13q313 −0.86 ND
hsa-miR-192 11q13.1 −1.43 Up [40]
hsa-miR-194 1q41/
11q13.1
−1.41 NC [40]
hsa-miR-20 13q313 −0.89 Up [47]
hsa-miR-30b 8q2422 −0.88 ND
hsa-miR-30 1p342 −1.37 ND
hsa-miR-455-3p 9q32 −0.79 ND
hsa-miR-885-5p 3p253 −2.79 ND
MicroRNA differentially expressed in HBT versus NT samples. MicroRNA analyzed in the study
and compared with data from literature (expression in HCC) are in bold face font.
*Values are calculated as mean[log2(HBT)] − mean[log2(NT)]: Down indicates downregulated in
HCC versus NT tissues; NC, no change in the expression pattern; ND, no data are available in the
literature; Up, upregulated in HCC versus NT tissues.
160 Hepatoblastoma and microRNA Magrelli et al. Translational Oncology Vol. 2, No. 3, 2009
level of significance (P < .05), are indicated. Unsupervised clustering
analysis using these 13 microRNA can discriminate tumor from non-
tumor tissues (data not shown), thus indicating that these microRNA
could be a valid diagnostic for HB, although the small number of
samples analyzed requires further future analyses.
Five MicroRNA Differentially Expressed in HB Showed a
Different Pattern Compared with HCC
Recent evidences published onHCCpoint out that specificmicroRNA
are involved in the onset and/or progression of the disease; our re-
sults were compared with different microRNA signatures published
(Table 2). We validated, by qRT-PCR, the microRNA that showed
a different pattern of expression compared with the HCC in all
matched samples (Table 2). Analysis of selected microRNA in
HB samples (Figure 2) showed that four of them were significantly
upregulated in the tumor compared with the nonmalignant tissue
(miR-214, miR-199a, miR-150 [P < .01], and miR-125a [P < .05])
and one was significantly downregulated (miR-148a [P < .01]). In
contrast, miR-106a, miR-145, miR-195, and miR-451 were not sig-
nificantly dysregulated (data not shown).
MicroRNA 214 and PTEN
The tumor suppressor PTEN is a negative regulator of the phos-
phoinositide 3-kinase signaling, and an alteration of this signaling
Figure 2. Validation of microRNA showing different pattern compared with HCC in nine HB patients and in nonneoplastic tissues. Each
histogram plots U6 normalized log2 fold change (ratio of tumors to nontumors). Error bars, SD of three replicas.
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cascade has been shown to give rise to different malignancies and can-
cer. Recent evidences show an active contribution of miR-214 and
miR-21 in controlling PTEN protein level. To verify the involvement
of miR-214 and miR-21 in HB samples, we measured miR-21 and
miR-214 expression levels by qRT-PCR; although miR-21 was not sig-
nificantly changed in all specimens, miR-214 showed an up-regulation
in the tumor versus nontumor tissues (Figure 3A). Furthermore, to assess
whether miR-214 exerts its function by transcript degradation or trans-
lational inhibition, PTEN protein levels were measured and found to be
decreased in HBT13/NT13, HBT15/NT15, and HBT17/NT17 sam-
ples (Figure 3B), thus showing an inverse correlation with miR-214.
In contrast, Pten messenger RNA was measured in all samples, and no
significant alterations were detected (data not shown).
Discussion
Research approaches to pediatric rare tumors are strongly linked
to the samples’ availability, and although markers (i.e., CTNNB1,
APC, IGF2) have been successfully used in the identification and
classification of liver cancers, in our study, the analysis of these genes
was not sufficient to characterize the differences between tumor and
nontumor samples. In fact, only two mutations were identified in
CTNNB1 gene, and no LOI was observed in our samples [44].
The low percentage of mutations in candidate genes and the ab-
sence of LOI observed in our study may be due to the limited num-
ber of samples, which often affects the analysis performed on rare
tumors. To tackle this issue, we used microRNA as a new potential
way to look for putative differences in rare cancers; actually, several re-
ports indicate that microRNA expression profile is a feasible method
for cancer classification [22].
In this study, global microRNA profiling identified differentially ex-
pressed microRNA that were commonly deregulated in HB patients.
We found that 33 of 51 filtered microRNA were differentially ex-
pressed: 21 of them resulted to be upregulated and 12 were down-
regulated. To the best of our knowledge, this is the first report
about microRNA in HB patients. Moreover, we found that several
microRNA showed a completely different behavior compared with
HCC. In fact, although miR-214, miR-199a, miR-150, and miR-
125a were upregulated in our matched samples, they were downreg-
ulated in HCC [38]. On the contrary, miR-148a was downregulated
in HB and upregulated in HCC [40].
Interestingly, miR-214 has been demonstrated to induce cell sur-
vival in ovarian cancer through targeting the 3′-untranslated region
of the Pten, thus leading to the down-regulation of its protein [32].
Other reports also indicate that PTEN protein levels are regulated by
miR-21 in HCC [31]. PTEN is instrumental in regulating the bal-
ance between growth and death in several cell types because it regu-
lates Akt signaling pathway and it is misregulated in several HB cases.
To assess the role of miR-214 or miR-21 in the regulation of PTEN,
we tested their expression level in our samples; although no significant
change in the miR-21 expression was observed, we found miR-214 to
be significantly upregulated in all our samples.
Although no significant variation on the messenger level of Pten
was detectable in tumors versus nontumor tissue samples, we ob-
served a significant reduction of PTEN protein in the three matched
frozen samples analyzed. We suggest that PTEN is negatively regu-
lated by miR-214 at the protein level and that down-regulation of
PTEN might correlate with elevated levels of miR-214.
Therefore, an active role of miR-214 in the activation of PTEN-
mediated AKT pathway, previously described in ovarian cancer [32],
could share common characteristics with other sporadic tumors; fur-
ther investigations on independent cohort of samples are needed to
shed light on the PTEN/AKT pathway and miR-214 in HB.
In conclusion, we pointed out for the first time that the expres-
sion pattern of 33 microRNA could represent a potential clue in
HB pathogenesis, and in particular, 13 microRNA could be func-
tional in discriminating tumor versus nontumor tissue. In addition,
five microRNA (miR-214, miR-199a, miR-150, miR-125a, and
miR-148a) were found to be helpful in discriminating HB from
HCC, thus representing valid markers for the classification of pediatric
liver tumors.
Future clarification of microRNA actions and functions will sub-
stantially improve our understanding of liver carcinogenesis. De-
velopment of drugs and molecules that specifically regulate hepatic
microRNA with subsequent normalization of altered target expres-
sion may lead to novel treatments for liver cancers.
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Figure 3. PTEN and miR-214 correlation of three patients from HB
frozen samples and relative nontumor tissues. (A) Quantitative re-
verse transcription–polymerase chain reaction microRNA analysis.
Bars display relative values of miR-214 expression in HB compared
with nontumor tissues (taken to 1). Error bars, SD of three replicas.
(B) Western blot analysis of variations in the expression of PTEN
protein and relative densitometry analysis. β-Actin was used as
loading control.
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